{"id":13942,"date":"2019-06-11T19:21:33","date_gmt":"2019-06-11T17:21:33","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=13942"},"modified":"2019-06-11T19:21:35","modified_gmt":"2019-06-11T17:21:35","slug":"pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/","title":{"rendered":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging"},"content":{"rendered":"\n

Pharming begint een klinisch onderzoek naar de effecten van\nrecombinant humane C1-esteraseremmer (rhC1INH); RUCONEST\u00ae, bij pati\u00ebnten met\npre-eclampsie (PE of zwangerschapsvergiftiging). Onlangs ontving Pharming hiervoor\ngoedkeuring door de medisch-ethische toetsingscommissie van het betreffende\nNederlandse klinische onderzoekscentrum.<\/p>\n\n\n\n

Sijmen de Vries, Chief Executive Officer van Pharming,\nzegt in reactie:<\/strong><\/p>\n\n\n\n

“Onze\nsterke prestaties in 2018 en het eerste kwartaal van 2019  hebben ons in\nstaat gesteld te investeren in toekomstige groei door de ontwikkeling van onze\npijplijn. Het is daarom dat we nu, na goedkeuring door de medisch-ethische\ncommissie, kunnen aanvangen met onze eerste pre-eclampsie-studie met RUCONEST\u00ae.<\/em><\/p>\n\n\n\n

In het eerste deel van het onderzoek zullen\nveiligheid en tolerantie bij een klein aantal pati\u00ebnten worden beoordeeld om\nhet veiligheidsprofiel van RUCONEST\u00ae te bevestigen, waarna wordt overgegaan tot\neen grotere pati\u00ebntenpopulatie. In dit tweede deel van het onderzoek zal een\nbredere groep pati\u00ebnten betrokken worden voor het eveneens beoordelen van de\nvoorlopige werkzaamheidsparameters. De resultaten worden gecombineerd en zullen\nnaar verwachting beschikbaar zijn in het derde kwartaal van 2020.<\/em><\/p>\n\n\n\n

Aangezien er momenteel geen goedgekeurde therapie\u00ebn tegen pre-eclampsie voorhanden zijn, kijken we uit naar de behandeling van de eerste pati\u00ebnten in deze studie. We willen deze thans nog volledig onvervulde medische behoefte aanpakken en de veiligheid en uitkomsten voor zwangere vrouwen en hun ongeboren baby’s met deze aandoening in de toekomst verbeteren.”<\/em><\/p>\n\n\n\n

Bron: Pharming<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Pharming begint een klinisch onderzoek naar de effecten van recombinant humane C1-esteraseremmer (rhC1INH); RUCONEST\u00ae, bij pati\u00ebnten met pre-eclampsie (PE of zwangerschapsvergiftiging). Onlangs ontving Pharming hiervoor goedkeuring door de medisch-ethische toetsingscommissie van het betreffende Nederlandse klinische onderzoekscentrum. Sijmen de Vries, Chief Executive Officer van Pharming, zegt in reactie: “Onze sterke prestaties in 2018 en het eerste […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-13942","post","type-post","status-publish","format-standard","hentry","category-gezondheid"],"acf":[],"yoast_head":"\nPharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Pharming begint een klinisch onderzoek naar de effecten van recombinant humane C1-esteraseremmer (rhC1INH); RUCONEST\u00ae, bij pati\u00ebnten met pre-eclampsie (PE of zwangerschapsvergiftiging). Onlangs ontving Pharming hiervoor goedkeuring door de medisch-ethische toetsingscommissie van het betreffende Nederlandse klinische onderzoekscentrum. Sijmen de Vries, Chief Executive Officer van Pharming, zegt in reactie: “Onze sterke prestaties in 2018 en het eerste […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-11T17:21:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-06-11T17:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Pharming start fase I\\\/II studie met Ruconest bij zwangerschapsvergiftiging\",\"datePublished\":\"2019-06-11T17:21:33+00:00\",\"dateModified\":\"2019-06-11T17:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/\"},\"wordCount\":235,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/\",\"name\":\"Pharming start fase I\\\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-06-11T17:21:33+00:00\",\"dateModified\":\"2019-06-11T17:21:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharming start fase I\\\/II studie met Ruconest bij zwangerschapsvergiftiging\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/","og_locale":"en_US","og_type":"article","og_title":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio","og_description":"Pharming begint een klinisch onderzoek naar de effecten van recombinant humane C1-esteraseremmer (rhC1INH); RUCONEST\u00ae, bij pati\u00ebnten met pre-eclampsie (PE of zwangerschapsvergiftiging). Onlangs ontving Pharming hiervoor goedkeuring door de medisch-ethische toetsingscommissie van het betreffende Nederlandse klinische onderzoekscentrum. Sijmen de Vries, Chief Executive Officer van Pharming, zegt in reactie: “Onze sterke prestaties in 2018 en het eerste […]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/","og_site_name":"hollandbio","article_published_time":"2019-06-11T17:21:33+00:00","article_modified_time":"2019-06-11T17:21:35+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging","datePublished":"2019-06-11T17:21:33+00:00","dateModified":"2019-06-11T17:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/"},"wordCount":235,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/","name":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-06-11T17:21:33+00:00","dateModified":"2019-06-11T17:21:35+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/pharming-start-fase-i-ii-studie-met-ruconest-bij-zwangerschapsvergiftiging\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Pharming start fase I\/II studie met Ruconest bij zwangerschapsvergiftiging"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/13942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=13942"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/13942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=13942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=13942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=13942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}